Patents by Inventor Si-Tse JIANG

Si-Tse JIANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Endoplasmic reticulum-targeting nanovehicles and methods for use thereof
    Patent number: 10912843
    Abstract: A method for treating a disease caused by protein retention in the endoplasmic reticulum (ER) with a sarcoplasmic/endoplasmic reticulum calcium ATPase pump inhibitor encapsulated in a polymer nanoparticle. The polymer nanoparticle is surface-modified such that it is targeted to the ER. The inhibitor reduces protein retention in the ER and the encapsulation lowers side effects of the inhibitor, e.g., cytotoxicity, as compared to administering the inhibitor without encapsulation. Also disclosed is a pharmaceutical composition that can be used for carrying out the method. Further provided is a transgenic mouse carrying in its genome a heterologous nucleic acid that encodes an H338Y mutant gp91phox protein. The transgenic mouse can serve as a model for human chronic granulomatous disease.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: February 9, 2021
    Assignee: National Cheng Kung University
    Inventors: Chi-Chang Shieh, Chia-Liang Yen, Dar-Bin Shieh, Si-Tse Jiang
  • ENDOPLASMIC RETICULUM-TARGETING NANOVEHICLES AND METHODS FOR USE THEREOF
    Publication number: 20190307894
    Abstract: A method for treating a disease caused by protein retention in the endoplasmic reticulum (ER) with a sarcoplasmic/endoplasmic reticulum calcium ATPase pump inhibitor encapsulated in a polymer nanoparticle. The polymer nanoparticle is surface-modified such that it is targeted to the ER. The inhibitor reduces protein retention in the ER and the encapsulation lowers side effects of the inhibitor, e.g., cytotoxicity, as compared to administering the inhibitor without encapsulation. Also disclosed is a pharmaceutical composition that can be used for carrying out the method. Further provided is a transgenic mouse carrying in its genome a heterologous nucleic acid that encodes an H338Y mutant gp91phox protein. The transgenic mouse can serve as a model for human chronic granulomatous disease.
    Type: Application
    Filed: January 31, 2019
    Publication date: October 10, 2019
    Inventors: Chi-Chang Shieh, Chia-Liang Yen, Dar-Bin Shieh, Si-Tse Jiang
  • Method of preventing polycystic kidney disease and PKD animal model with exogenous neutrophil gelatinase-associated lipocalin
    Patent number: 10307461
    Abstract: Disclosed is a method of treating or preventing polycystic kidney disease (PKD) by administration of neutrophil geleatinase-associated lipocalin (Ngal) protein. Also, a transgenic non-human animal model is established to investigate the effect of overexpression of exogenous Ngal on PKD progression.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: June 4, 2019
    Assignee: NATIONAL TAIWAN NORMAL UNIVERSITY
    Inventors: Hsiu-Mei Hsieh, Yi-Ren Wang, Si-Tse Jiang, Wen-Yih Jeng, Yuan-Yow Chiou
  • METHOD OF TREATING OR PREVENTING POLYCYSTIC KIDNEY DISEASE AND PKD ANIMAL MODEL WITH EXOGENOUS NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN
    Publication number: 20170182120
    Abstract: Disclosed is a method of treating or preventing polycystic kidney disease (PKD) by administration of neutrophil geleatinase-associated lipocalin (Ngal) protein. Also, a transgenic non-human animal model is established to investigate the effect of overexpression of exogenous Ngal on PKD progression.
    Type: Application
    Filed: July 27, 2016
    Publication date: June 29, 2017
    Inventors: Hsiu-Mei HSIEH, Yi-Ren WANG, Si-Tse JIANG, Wen-Yih JENG